Liposomal drug delivery

Cancer Treatment Reviews

Volumn 22, Issue 5, 1996, Pages 365-379

  Ranson, M ^a   Howell, A ^a   Cheeseman, S ^a   Margison, J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CARDIOMYOPATHY; CHILL; CLINICAL TRIAL; DRUG CLEARANCE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; LEUKOPENIA; LUNG TOXICITY; MULTIDRUG RESISTANCE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0030430048     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90009-2     Document Type: Article

References (137)

1. Bangham, A. D. Standish, M. M. & Watkins, J. C. (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13: 238-252.
2. Sessa, G. & Weissmann, G. (1968) Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9: 310-318.
3. Bangham, A. D. (1968) Membrane models with phospholipids. Prog. Biophys. Mol. Biol. 18: 29-95.
4. Bangham, A. D., Hill, M. W. & Miller, N. G. A. (1974) Preparation and use of liposomes as models of biological membranes. Meth Membrane Biol 1: 1-68.
5. Senior, J. H. (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Ther. Drug Carrier Syst. 3: 123-193.
6. Beaumier, P. L. & Hwang, K. J. (1983) Effect of liposome size on degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver. Biochim Biophys Acta 731: 23-30.
7. Allen, T. M. & Chonn, A. (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS-Lett. 223: 42-46.
8. Gabizon, A. & Paphadjopoules, D. (1988) Liposomal formulation with prolonged circulation time in blood and enhanced uptake in tumours. Proc. Natl. Acad. Sci. USA 85: 6949-6953.
9. Woodle, M. C. & Lasic, D. D. (1992) Sterically stabilized liposomes. Biochem. Biophys. Acta 1113: 171-199.
10. Lasic, D. D., Martin, F. J., Gabizon, A., Huang, S. K. & Papahadjopoulos, D. (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070: 187-192.
11. Durocher, J. R., Payne, R. C. & Conrad, M. E. (1975) Role of sialic acid in erythrocyte survival. Blood 45: 11-20.
12. Jones, M. V. & Nicholas, A. R. (1991) The effect of blood serum on the size and stability of phospholipid liposomes. Biochim. Biophys. Acta 1065: 145-152.
13. Scherphof, G. & Morselt, H. (1984) On the size dependent disintegration of small unilamellar phosphatidylcholine vesicles in rat plasma. Evidence of complete loss of vesicle structure. Biochem. J. 221: 423-429.
14. Gabizon, A., Price, D. C., Huberty, J., Bresalier, R. S. & Papahadjopoulos, D. (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors, biodistribution and imaging studies. Cancer Res. 50: 6371-6378.
15. Vaage, J., Barbera-Guillem, E., Abra, R., Huang, A. & Working, P. (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 73: 1478-1484.
16. Gabizon, A., Isaacson, R., Libson, E et al. (1994) Clinical studies of liposome encapsulated doxorubicin. Acta Oncol. 33: 779-786.
17. Gabizon, A., Catane, R., Uziely, B et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54: 987-992.
18. Gabizon, A. A. (1992) Selective tumour localisation and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes. Cancer Res. 52: 891-896.
19. Gabizon, A., Chisin, R., Druckmann, S et al. (1991) Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64: 1125-1132.
20. Mori, A., Wu, S. P., Han, I., Khakhar, A. R., Perez-Soler, R. & Huang, L. (1996) In vivo activity of cis-bis-neodecanoato-trans-R,R-1,2 diaminocyclohexane platinum (II) formulated in long circulating liposomes. Cancer Chemother. Pharmacol. 37: 435-444.
21. Gondal, J. A., Preuss, H. G., Swartz, R. & Rahman, A. (1993) Comparative pharmacological, toxicological and anti-tumoural evaluation of free and liposome encapsulated cisplatin in rodents. Eur. J. Cancer 29A: 1536-1542.
22. Papahadjopoulos, D., Allen, T., Gabizon, A et al. (1991) Sterically stabilized liposomes improvement in pharmacokinetics and antitumour therapeutic efficacy. Proc. Nat. Acad. Sci. USA 88: 11460-11464.
23. Abra, R. M. & Hunt, C. A. (1981) Liposome disposition in vivo III Dose and vesicle size. Biochim. Biophys. Acta. 660: 493-503.
24. Janknegt, R., de-Marie, S., Bakker-Woudenberg, I. A. & Crommelin, D. J. (1992) Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokinet. 23: 279-291.
25. de Marie, S. (1996) Liposomal and lipid based formulations of Amphotericin B. Leukaemia 10 (Suppl. 2) S93-96.
26. Bakker-Woudenberg, I. A., Len-Kate, M. T., Stearne-Cullen, L. E. & Woodle, M. C. (1994) Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localisation in Klebsiella pneumoniae infected lung tissue. J. Infect. Dis. 171: 938-947.
27. Alving, C. R. (1995) Lipopolysaccharide, lipid A and liposome containing lipid A as immunologic adjuvants. Immunobiology 187: 430-446.
28. Gregoriadis, G. (1990) Immunological adjuvants: a role for liposomes. Immunol. Today 11: 89-97.
29. Park, J. W., Hong, K., Carter, P et al. (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92: 1327-1331.
30. Vingerhoeds, M. H., Storm, G. & Crommelin, D. J. (1994) Immunoliposomes in vivo. Immunomethods 4: 259-272.
31. Anderson, P. M., Hansen, D. C., Hasz, D. E., Halet, M. R., Blazar, B. R. & Ochöa, A. C. (1994) Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and IFN gamma. Cytokine 6: 92-101.
32. Cooper, M. J. (1996) Noninfectious gene transfer and expression systems for cancer gene therapy. Semin. Oncol. 23: 172-187.
33. Woll, P. J. & Hart, I. R. (1995) Gene therapy for lung cancer. Ann. Oncol. 6 (Suppl. 1): 73-77.
34. Farhood, H., Gao, X., Son, K et al. (1994) Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann. N.Y. Acad. Sci. 716: 23-35.
35. Juliano, R. L. & Akhtar, S. (1992) Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Dev. 2: 165-176.
36. Kartner, N., Riordan, J. R. & Ling, V. (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285-1288.
37. Deffie, A. M., Batra, J. K. & Goldenberg, G. G. (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin sensitive and resistant P388 leukaemia cell lines. Cancer Res. 49: 58-65.
38. Mayhew, E. G., Lasic, D., Babbar, S. & Martin, F. J. (1992) Pharmacokinetics and antitumor activity of epirubicin encapsulated in long circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer 51: 302-309.
39. Vaage, J., Mayhew, E., Lasic, D. & Martin, F. (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 51: 942-948.
40. Williams, S. S., Alosco, T. R., Mayhew, E., Lasic, D. D., Martin, F. J. & Banhert, R. B. (1993) Arrest of human lung tumour xenograft growth in SCID mice using doxorubicin encapsulated in sterically stabilised liposomes. Cancer Res. 53: 3964-3967.
41. Masood, R., Husain, S.R., Rahman, A. & Gill, P. (1993) Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS-Res-Hum-Retroviruses 9: 741-746.
42. Forssen, E. A. (1988) Chemotherapy with anthracycline liposomes. In: Gregoriadis, G., ed. Liposomes as Drug Carriers: Recent Trends and Progress. Chichester: John Wiley, pp. 355-364.
43. Forssen, E. A., Coulter, D. M. & Proffitt, R. T. (1992) Selective in vivo localisation of Daunorubicin small unilamellar vesicles in solid tumours. Cancer Res. 52: 3255-3261.
44. Forssen, E. A. & Ross, M. E. (1994) Daunoxome treatment of solid tumors: preclinical and clinical investigations. J. Liposome Res. 4: 481-512.
45. Kanter, P. M., Bullard, G. A., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R. & Pavelic, Z. P. (1993) Pre-clinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicins and empty liposomes in mice and dogs. In Vivo 7: 17-26.
46. Kanter PM, Bullard, G. A., Ginsberg, R. A et al. (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7: 85-95.
47. Kanter, P. M., Klaich, G., Bullard, G. A., King, J. M. & Pavelic, Z. P. (1994) Pre-clinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs. In Vivo 8: 975-982.
48. Thierry, A. R., Vige, D., Couglin, S. S., Belli, J. A., Dritschilo, A. & Rahman, A. (1993) Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB J. 7: 572-579.
49. Thierry, A. R., Rahman, A. & Dritschillo, A. (1994) A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumor cells. Cancer Chemother. Pharmacol. 35: 84-88.
50. Oudard, S., Thierry, A., Jorgensen, T. J. & Rahman, A. (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin. Cancer Chemother. Pharmacol. 28: 259-265.
51. Merlin, J. L., Marchai, S., Ramacci, C., Notter, D. & Vigneron, C. (1995) Modulation of daunorubicin intracellular accumulation of P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Int. J. Hyperthermia 11: 855-865.
52. Hu, YP., Henry-Toulme, N. & Robert, J. (1995) Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in-vitro model of rat glioblastoma cells. Eur. J. Cancer 31A: 389-394.
53. Forssen, E. A., Male-Brune, R., Adler-Moore J. P et al. (1996) Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue. Cancer Res. 56: 2066-2075.
54. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S. & Papahadjopoulos, D. (1992) Microscope localization of sterically stabilized liposomes in colon carcinoma bearing mice. Cancer Res. 52: 5135-5143.
55. Van-Bree C., Krooshoop, J. J., Rietbroek, R. C., Kipp, J. B. & Bakker, P. J. (1996) Hyperthermia enhances tumour uptake and antitumoral efficacy of thermostable liposomal daunorubicin in a rat solid tumour. Cancer Res. 56: 563-568.
56. Lee, R. J. & Low, P. S. (1995) Folate-mediated tumor cell targeting of liposome entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233: 134-144.
57. Akaishi, S., Kobari, M., Takeda, K. & Matsumo, S. (1995) Targeting chemotherapy using antibody-combined liposome against human pancreatic cancer cell-line. Tohoku J. Exp. Med. 175: 29-42.
58. Ahmad, I. & Allen, T. M. (1992) Antibody-mediated specific binding and cytotoxicity of liposome entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52: 4817-4820.
59. Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I. & Barenholtz, Y. (1996) Preparation and characterisation of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm. Res. 13: 352-359.
60. Suzuki, S., Uno, S., Fukuda, Y., Aoki, Y., Masuko, T. & Hashimoto, Y. (1995) Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer 72: 663-668.
61. Vingerhoeds, M. H., Steerenberg, P. A., Hendricks, J. J. G. W. et al. (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer 74: 1023-1029.
62. Mayer, L. D., Tai, L. C., Ko, D. S., Masin, D., Ginsberg, R. S., Cullis, P. R. & Bally, M. B. (1989) Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49: 5922-5930.
63. Bally, M. B., Masin, D., Nayar, R., Cullis, P. R. & Mayer, L. D. (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor bearing mice. Cancer Chemother. Pharmacol. 34: 137-146.
64. Bally, M. B., Nayer, R., Masin, D., Cullis, P. R. & Mayer, L. D. (1990) Studies on the myelosuppressive activity of doxorubicin entrappped in liposomes. Cancer Chemother. Pharmacol. 27: 13-19.
65. Vaage, J., Donovan, D., Mayhew, E., Ulster, P. & Woodle, M. (1993) Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int. J. Cancer 54: 959-964.
66. Mickisch, G. H., Rahman, A., Pastan, I. & Gottesman, M. M. (1992) Increased effectiveness of liposome-encapsulated doxorubicin in multidrug resistant transgenic mice compared with free doxorubicin. J. Natl. Cancer Inst. 84: 804-805.
67. Mayer, L. D., Bally, M., Cullis, P. R., Wilson, S. L. & Emerman, J. T. (1990) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumour efficacy in the SC115 murine mammary tumor. Cancer Lett. 53: 183-190.
68. Vaage, J., Donovan, D., Mayhew, E., Abra, R. & Huang, A. (1993) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72(12): 3671-3675.
69. Cowens, J. W., Creaven, P. J., Greco, W. R. et al. (1993) Initial clinical (Phase I) trial of TLC D-99 doxorubicin encapsulated in liposomes. Cancer Res. 53: 2796-2808.
70. Conley, B. A., Egorin, M. J., Whitacre, M. Y., Carter, D. C., Zuhowski, E. G. & Van-Echo, D. A. (1993) Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother. Pharmacol. 33: 107-112.
71. Guaglianone, P., Chan, K., DelaFlor-Weiss E et al. (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest. New Drugs 12: 103-110.
72. Law, T. M., Mencel, P. & Motzer, R. J. (1994) Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest. New Drugs 12: 323-325.
73. Gabizon, A., Peretz, T., Sulkes, A et al. (1989) Systemic administration of doxorubicin-containing liposomes: a phase I study. Eur. J. Cancer Clin. Oncol. 25: 1795-1803.
74. Gabizon, A., Shiota, R. & Papahadjopoulos, D. (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in liposomes with long circulation times. J. Natl. Acad. Inst. 81: 1484-1488.
75. Treat, J., Greenspan, A., Font Sanchez J. A. et al. (1990) Antitumour activity of liposome entrapped doxorubicin in advanced breast cancer a phase II study. J. Natl. Cancer Inst. 82: 1706-1710.
76. Fischl, M. A., Krown, S. E., O'Boyle, K. P. et al. and the AIDS clinical trials group (1993) Weekly doxorubicin in the treatment of patients with AIDS related Kaposi's sarcoma. J. Acquir. Immune Deficiency Syndr. 6: 259-264.
77. Remick, S. C., Reddy, M., Herman, D et al. (1994) Continuous infusion bleomycin in AIDS related Kaposi's sarcoma. J. Clin. Oncol. 12: 1130-1136.
78. Mintzer, D., Real, F. X., Jovino, L. & Krown, S. E. (1985) Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann. Int. Med. 102: 200-202.
79. Laubenstein, L. J., Kriegel, R. L., Odajnyk, C. M et al. (1984) Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J. Clin. Oncol. 2: 1115-1120.
80. Volberding, P. A., Abrams, D. I., Conant, M., Kaslow, K., Vranizan, K. & Ziegler, J. (1985) Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103: 335-338.
81. Shepherd, F. A., Burkes, R. L., Paul, K. E. & Goss, P. E. (1991) A phase II study of 4′-epirubicin in the treatment of poor risk Kaposi's sarcoma and AIDS. AIDS 5: 305-309.
82. Gill, P. S., Rarick, M. U., Espina, B. et al. (1990) Advanced acquired immunodeficiency syndrome related Kaposi's sarcoma. Results of pilot studies using combination chemotherapy. Cancer 65: 1074-1078.
83. Gill, P. S., Miles, S. A., Mituyasu, R. T et al. (1994) Phase I clinical trials group (075) study of adriamycin, bleomycin, and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 8: 1695-1699.
84. Lassoued, K., Clauvel, J. P., Katlama, C., Janier, M., Picard, C. & Matherson, S. (1990) Treatment of the acquired immunodeficiency syndrome related Kaposi's sarcoma with bleomycin as a single agent. Cancer 66: 1869-1872.
85. Gill, P. S., Rarick, M., McCutchan, J. A et al. (1991) Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am. J. Med. 90: 427-433.
86. Hengge, U. R. & Brockmeyer, N. H. (1993) Liposomal doxorubicin in AIDS related Kaposi's sarcoma. Lancet 342: 497.
87. Simpson, J. K., Miller, R. F. & Spittle, M. F. (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin. Oncol. R. Coll. Radiol. 5: 372-374.
88. James, N. D., Coker, R. J., Tomlinson, D et al. (1994) Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. 6: 294-296.
89. Bogner, J. R., Kronawitter, U., Rolinski, B., Trueenbach, K. & Goebel, F. D. (1994) Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. J. Acquir. Immune Def. Syndr. 7: 463-468.
90. Harrison, M., Tomlinson, D. & Stewart, S. (1995) Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13: 914-920.
91. Goebel, F. D., Goldstein, D., Goos, M., Jablonowski, H., Stewart, J. S. (1996) Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer 73: 989-994.
92. Northfelt, D. W., Dezube, B., Miler, B., Mamelok, R. D., DuMond, C. E. & Henry, D. (1995) Randomized comparative trial of Doxil versus adriamycin, bleomycin and vincristine in the treatment of severe AIDS-related Kaposi's sarcoma. Blood 86 (Suppl. 1): 382a.
93. Stewart, S., Jablonowski, H., Goebel, H., L'Age, M., Spittle, M. & Luthy, R. and the DOXIL trials groups (1996) Randomized comparative trial of DOXIL versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. XI International Conference on AIDS, July 1996, Abst 6026.
94. Presant, C. A., Scolaro, M., Kennedy, P et al. (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242-1243.
95. Gill, P. S., Wernz, J., Scadden, D. T et al. (1996) Randomised Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14: 2353-2364.
96. Forssen, E. A. & Tokes, Z. A. (1981) Use of amnionic liposomes for reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA 78: 1873-1877.
97. Rahman, A., Kessler, A., More, N et al. (1982) Liposomal protection of adriamycin induced cardiotoxicity in mice. Cancer Res. 40: 1532-1537.
98. Gabizon, A., Meshorer, A. & Barenholtz, Y. (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 77: 459-469.
99. Berry, G., Billingham, M., Alderman E et al. (1996) Reduced cardiotoxicity of DOXIL (Pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma. Patients compared to a matched control group of cancer patients given doxorubicin. Proc. Am. Soc. Clin. Oncol.: Abst 843.
100. Gill, P. S., Espina, B. M., Muggia, F et al. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13: 996-1003.
101. Uziely, B., Jeffers, S., Isacson, R et al. Liposomal doxorubicin, antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol. 13: 1777-1785.
102. Ranson, M., O'Byrne, K., Carmichael, J. & Howell, A. (1996) Phase II dose finding trial of DOXSL (Stealth liposomal doxorubicin HCL) in the treatment of advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 15: Abst 161.
103. Van Oosterom, A. T., Mouridsen, H. T., Wilders, J et al. (1986) Carminomycin versus doxorubicin in advanced breast cancer, a randomized study of the EORTC breast cancer cooperative group. Eur. J. Cancer Clin. Oncol. 22: 601-605.
104. Lawton, P. A., Spittle, M. R., Ostrowki, M. J et al. (1993) A comparison of doxorubin, epirubicin and mitozantrone as single agents in advanced breast cancer. Clin. Oncol. 5: 80-84.
105. Pfeiffer, P., Cold, S. & Rose, C. (1992) Cytotoxic treatment of metastatic breast cancer. Acta Oncol. 31: 219-224.
106. Legha, S. S., Hortobaghi, G. N., Benjamin, R. S. (1987) Anthracylines. In: Lokich, J. J., ed., Cancer Chemotherapy by Infusion. Chicago Precept Press, pp. 100-113.
107. Gordon, K. B., Tajuddin, A., Guitart Kuzel, T. M., Eramo, L. R. & VonRoenn, J. (1995) Hand Foot syndrome associated with liposome encapsulated doxorubicin therapy. Cancer 75: 2169-2173.
108. Richardson, D. S., Tiche, M., Johnson, S. A., Kelsey, S. M. & Newland, A. C. (1966) Treatment of relapsed and resistant lymphoma with liposomal daunorubicin (Daunoxome, Nexstar). Procedings Br. Soc. Haematol. 1990: Abstract 63.
109. Hupperts, P. S. G. J., Erdkamp, F. L. G., Ten Bokkel-Huinink, W. W., Nuyts, G. D., Eestermans, G. H. & Ross, M. E. (1995) Phase II study of liposomal encapsulated daunorubicin (Daunoxome) in advanced breast cancer. Proceedings San Antonio Meeting Breast Cancer Research and Treatment, Abstract 244.
110. Eckardt, J. R., Campbell, E., Burris, H. A et al. (1994) A Phase II trial of Daunoxome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am. J. Clin. Oncol. 17: 498-501.
111. Embree, L., Gelmn, K. A., Lohr, A et al. (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J. Pharm. Sci. 82: 627-634.
112. Fonseca, G. A., Valero, V., Buzdar, A et al. (1995) Phase II study of TLC D-99 (liposomal doxorubicin) in patients with metastatic breast carcinoma. Proc. Am. Soc. Clin. Oncol. 14: Abst 95.
113. Viens, P., Baume, D., Touinssi, M et al. (1994) Tolerance and pharmacokinetic study of liposomal doxorubicin (TLC D-99) in patients with refractory cancer. Proc. Am. Soc. Clin. Oncol. 13: Abst 432.
114. Aiba, K., Bessho, A., Horikoshi, N et al. (1994) A Phase I clinical trial of lipodox (doxorubicin encapsulated in liposomes). Proc. Am. Soc. Clin. Oncol. 13: Abst 445.
115. O'Day, S. J., Mazanet, R., Skarin, A. T., Salgia, R., Gordon, D. & Elias, A. D. (1994) Dose escalation of liposome encapsulated doxorubicin (D-99) with G-CSF support in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 13: Abst 406.
116. Mazanet, R., Seidenberg, S., Bartel, S., Elias, A. & Saletan, S. (1993) A phase I study of liposome encapsulated doxorubicin (TLC D-99) with G-CSF. Proc. Am. Soc. Clin. Oncol. 12: Abst 415.
117. Early, E., Shorter, S., Sugarman, A et al. (1996) Phase I trial of dose intense liposomal encapsulated doxorubicin with G-CSF in patients with advanced soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 15: Abst 1690.
118. Shapiro, C. L., Ervin, T., Azarnia, N et al. and the D-99 study group (1996) Phase II trial of high dose liposome encapsulated doxorubicin (D-99) with G-CSF in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15: Abst 115.
119. Gondal, J. A., Preuss, H. G., Swartz, R. & Rahman, A. (1993) Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur. J. Cancer 29A: 1536-1542.
120. Mizuno, I., Yasui, T., Takeyama, H et al. (1995) Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis. Gan To Kagaku Ryoho 22: 1598-1601.
121. Steerenberg, P. A., Storm, G., de Groot, G et al. (1988) Liposomes as drug carrier system for cis-diaminedichloroplatinum (II): Antitumour activity in vivo, induction of drug resistance, nephrotoxicity, and platinum distribution. Cancer Chemother. Pharmacol. 21: 299-307.
122. Allen, T. M., Mehra, T., Hansen, C. & Chin, Y. C. (1992) Stealth Liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 52: 2431-2439.
123. Kanter, P. M., Klaich, G. M., Bullard, G. A., King, J. M., Bally, M. B. & Mayer, L. D. (1994) Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5: 579-590.
124. Webb, M. S., Harasym, T. O., Masin, D., Bally, M. B. & Mayer, L. D. (1995) Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72: 896-904.
125. Mayer, L. D., Masin, D., Nayar, R., Boman, N. L. & Bally, M. B. (1995) Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br. J. Cancer 71: 482-488.
126. Vaage, J., Donovan, D., Mayhew, E., Uster, P. & Woodle, M. (1993) Therapy of mouse mammary carcinoma with vincristine and doxorubicin in sterically stabilised liposomes. Int. J. Cancer 54: 959-964.
127. Vaage, J., Donovan, D., Loftus, T., Ulster, P. & Working P. (1995) Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristine encapsulated in sterically stabilized liposomes. Eur. J. Cancer 31A: 367-372.
128. Allen, T. M., Newman, M. S., Woodle, M. C., Mayhew, E. & Uster, P. S. (1995) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 62: 199-204.
129. Sharma, A. & Straubinger, R. M. (1994) Novel taxol formulations, preparation and characterisation of taxol-containing liposomes. Pharm. Res. 11: 889-896.
130. Straubinger, R. M., Sharma, A., Murray, M. & Mayhew, E. (1993) Novel taxol formulations. Monogr. Natl. Cancer Inst. 69-78.
131. Sharma, A., Mayhew, E. & Straubinger, R. M. (1993) Antitumor effect of taxol containing liposomes in a taxol resistant murine tumor model. Cancer Res. 53: 5877-5881.
132. Sharma, A., Straubinger, R. M., Ojima I. & Bernacki, R. J. (1995) Antitumor efficacy of taxane liposomes on a human ovarian xenograft in nude athymic mouse. J. Phar. Sci. 84: 1400-1404.
133. Riondel, J., Jacrot, M., Fessi, H., Puisieux, F. & Potier, N. (1992) Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6: 23-27.
134. Kedar E, Rutkowski Y, Braun, E., Emanuel, N. & Barenholz, Y. (1994) Delivery of cytokines by liposomes. 1. Preparation and characterisation of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. Emphasis Tumor Immunol. 16: 47-59.
135. Kedar, E., Braun, E., Rutlowski, Y., Emmanuel, N. & Barenholtz, Y (1994) Deliverty of cytokines in liposomes II-IL-2 encapsulated in long circulating sterically stabilized liposomes: immunomodulatory and antitumor activity in mice. J. Immunother. Emphasis Tumor Immunol. 16: 115-124.
136. Wasan, K. M. & Lopez-Berenstein, G. (1995) The past present and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol 17: 1-15.
137. Mizuguchi, H., Nakanishi, M., Nakanishi, T., Nakagawa, S. & Mayumi, T. (1996) Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Br. J. Cancer 73: 472-476.